S100A4‐negative stage III colon cancer patients had an estimated 3‐year relapse‐free survival of 66% and 55% in cohorts 1 and 2, respectively, implying that these patients likely would benefit from additional treatment. Here, S100A4 is linked to malignant colon neoplasm.